



**Predictive
Oncology**[®]

www.predictive-oncology.com

Minnesota
(Headquarters)

2915 Commers Drive
Suite 900
Eagan, MN 55121

(651) 389-4800

Pennsylvania

91 43rd Street
Suite 110
Pittsburgh, PA 15201

(412) 432-1500
(800) 547-6165 Client Services

Alabama

200 Riverhills Business Park,
Suite 250
Birmingham, AL 35242

(205) 922-5400

ACE (Accelerating Compound Exploration) Program

Invitation Only

Submission Deadline: March ^{31st}, 2023

What is the ACE Program?

Predictive Oncology is committed to bringing better oncology treatments to patients, faster. To advance toward our goal, the ACE (Accelerating Compound Exploration) program has been created to grant early-stage academic drug development groups access to Predictive Oncology's PEDAL platform which relies on an extensive biobank of privately held tumor samples. Through ACE, academic investigators (PI) will obtain access to PEDAL to help evaluate their drug compounds and enable more informed selection of drug/tumor type combinations to increase the probability of future clinical success by efficiently addressing tumor heterogeneity earlier in development. Thus, strengthening the data package for preclinical drug compounds. This program will be provided at no up-front cost to the investigator or institution.

PEDAL is an AI-driven platform that pairs active machine learning with drug screening results generated in our state-of-the-art laboratory, using a biobank of more than 150,000 tumor samples. The intersection of these two approaches affords researchers the opportunity to explore an otherwise unreachable experimental space and to pinpoint the best drug candidates to take forward in the development process. Additional information about PEDAL can be found [here](#).

This program aims to shorten the time necessary to identify impactful drug candidates and to circumvent funding limitations that might otherwise prevent those drugs from reaching the clinic. In addition, we aim to assist in re-evaluating small molecules that have otherwise not had sufficient traction to reach the market.

Eligibility

Principal Investigators associated with drug development initiatives at their respective institutions are encouraged to submit their drug candidates for consideration. Technology transfer offices may also submit existing compounds for the project. PIs must be an independent investigator or a postdoctoral fellow. Institutions can submit more than one application. Communication about drug candidates should be submitted to ace@predictive-oncology.com.

Project Specifics

Once a drug compound is selected for inclusion in the ACE program:

- The PI will work directly with the Predictive Oncology scientific teams to set up their drug compounds in PEDAL and in our laboratory.
- Predictive Oncology will include the drug compound(s) during an upcoming PEDAL campaign, using the machine learning process to screen the compound(s) against tumor samples as directed by the predictive model.
- Resultant raw data will be aggregated, summarized for the PI and reviewed with the Predictive Oncology team.

Submission Process

- Drug compound information must be submitted by March 31, 2023, to: ace@predictive-oncology.com
- Candidate drugs that meet the inclusion criteria for PEDAL platform will proceed through technical feasibility and overall impact reviews by Predictive Oncology's scientific team which may include request for submission of additional information.

Information Required for Submission

The following information about your drug compound(s) and PI must(*) be provided:

- Name and email of PI
- Name of academic institution
- What is the intended drug target?
- What is the MOA?
- What is the target organ system/disease state?
- What is the purpose or potential impact of small molecule intervention?
- Is the candidate novel or repurposed?
- Are there any publications related to your compound(s)?
- Do you currently have stock of the candidate drug in lyophilized format?
- SMILES file
- Molecular weight of your compound
- Available information on preferred solute and solubility profile.
- What is the defined dosage range for in vitro assays?
- IC50, if available

Questions?

Amy Ewing, Clinical Projects Manager – ace@predictive-oncology.com

Additional References:

[PeDAL Advanced Look - Predictive Oncology \(predictive-oncology.com\)](https://predictive-oncology.com)